The overall objective of this study is to assess the efficacy and safety of two dosing
regimens of gemcabene (300 mg once daily for 24 weeks or 300 mg daily for 12 weeks followed
by 600 mg daily for 12 weeks) in up to eight patients with Familial Partial Lipodystrophy
with high triglycerides and Non-Alcoholic Fatty Liver Disease. The study will consist of a
six week Wash Out Period, up to a 28 day Screening Period, a 24 week Treatment Period, and a
follow-on safety assessment four weeks post final dose. Study participation will last
approximately 4 months and includes at least 9 study visits, and can be as many as 11 study
visits.